[an error occurred while processing this directive] | [an error occurred while processing this directive]
Treatment options of early-stage lung cancer:surgery or stereotactic body radiotherapy
Wu Yanling,Feng Qingfu,Wang Xiaodan,Zeng Qiang
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing 100021,China
Abstract For the treatment of early non-small cell lung cancer,surgery is still one of the most important curative treatments. Lung segment or subsegment resection under video-assisted thoracoscopic surgery is becoming more and more popular. With the development of radiotherapy technology, Stereotactic Body Radiotherapy (SBRT) has achieved the similar or the same curative effect as surgery. It has become an indisputable curative treatment for patients who can not or refuse surgery,and there are still some disputes among those who can operate. Therefore,this review will elaborate on these treatment methods in order to help update the concept and provide more treatment methods and obtain more benefits for patients. Although it is no randomized clinical trial to compare SBRT with surgery,we suggest that SBRT is the curative treatment for patients who can not or refuse surgery. Especially for the elderly,or patients with cardiopulmonary diseases,diabetes and other high-risks. SBRT should become the main treatment methods,because its curative effect is not inferior to surgery and its complications are fewer and lighter. Therefore,for the treatment of non-small cell lung cancer in the early stage,it is more importent to choose individualized treatment methods so as to more benefit.
Wu Yanling,Feng Qingfu,Wang Xiaodan et al. Treatment options of early-stage lung cancer:surgery or stereotactic body radiotherapy[J]. Chinese Journal of Radiation Oncology, 2019, 28(9): 709-712.
Wu Yanling,Feng Qingfu,Wang Xiaodan et al. Treatment options of early-stage lung cancer:surgery or stereotactic body radiotherapy[J]. Chinese Journal of Radiation Oncology, 2019, 28(9): 709-712.
[1] Chen WQ,Zheng RS,Baade PD,et al. Cancer statistics in China,2015[J]. CA Cancer J Clin,2016,66(1):115-132. DOI:10.3322/caac.21338. [2] Chi A,Liao Z,Nguyen NP,et al. Systemic review of the patterns of failure following stereotactic body radiation therapy in early-stage non-small-cell lung cancer:clinical implications[J]. Radiother Oncol,2010,94(1):1-11. DOI:10.1016/j.2009.12.008. [3] Ginsberg RJ,Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1N0 non-small cell lung cancer[J]. Ann Thorac Surg,1995,60:615-623. DOI:10.1016/0003-4975(95)00537-U. [4] Palma DA,Senan S. Improving outcomes for high-risk patients with early-stage non-small-cell lung cancer:insights from population-based data and the role of stereotactic ablative radiotherapy[J]. Clin Lung Cancer,2013,14(1):1-5. DOI:10.1016/j.cllc.2012.06.005. [5] Fan J,Wang L,Jiang GN,et al. Sublobectomy versus lobectomy for stage Ⅰ non-small-cell lung cancer,a Meta-analysis of published studies[J]. Ann Surg Oncol,2012,1 9:661-668. DOI:10.1245/s10434-011-1931-9. [6] Nakamura K,Saji H,Nakajima R,et al. A phase Ⅲ randomized trial of lobectomy versus limited resection for small-sized peripheral non-small cell lung cancer (JCOG0802/WJOG4607L)[J]. Jap J Clin Oncol,2010,40(2):271-274. DOI:10.1245/s10434-011-1931-9. [7] Cao C,Chandrakumar D,Gupta S,et al. Could less be more?-A systematic review and meta-analysis of sublobar resections versus lobectomy for non-small cell lung cancer according to patient selection[J]. Lung Cancer,2015,89(1):121-132. DOI:10.1016/j.lungcan.2015.05.010. [8] Bedetti B,Bertolaccini L,Rocco R,et al. Segmentectomy versus lobectomy for stage Ⅰ non-small cell lung cancer:a systematic review and meta-analysis[J]. J Thorac Dis,2017,9(6):1615-1623. DOI:10.21037/jtd.2017.05.79. [9] Wisnivesky J,Bonomi M,Henschke C,et al. Radiation therapy for treatment of unresected stage Ⅰ-Ⅱ non-small cell lung cancer[J]. Chest,2005,128(3):1461-1467. DOI:10.1378/chest.128.3.1461. [10] McGarry R,Song G,Rosiers P,et al. Observation-only management of early stage,medically inoperable lung cancer:Poor outcome[J]. Chest,2002,21(4):1155-1158. DOI:10.1378/chest.121.4.1155. [11] Onishi H,Shirato H,Nagata Y,et al. Stereotactic body radiotherapy (SBRT) for operable stage Ⅰ non-small-cell lung cancer:can SBRT be comparable to surgery?[J]. Int J Radiat Oncol Biol Phys,2011,81(5):1352-1358. DOI:10.1016/j.ijrobp.2009.07.1751. [12] Ginsberg R,Rubinstein L. Randomized trial of lobectomy versus limited resection for T1 N0 nonsmall cell lung cancer[J]. Ann Thorac Surg,1995,60(3):615-622. [13] Lagerwaard F,Verstegen N,Haasbeek C,et al. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage Ⅰ non-small cell lung cancer[J]. Int J Radiat Oncol Biol Phys,2012,83(1):348-53. DOI:10.1016/j.ijrobp.2011.06.2003. [14] Nagata Y,Hiraoka M,Shibata T,et al. A phase Ⅱ trial of stereotactic body radiation therapy for operable TIN0M0 non-small cell lung cancer:Japan clinical oncology group (JCOG0403)[J]. Int J Radiat Oncol Biol Phys,2010,78:S27(abstr). [15] Timmerman RD,Paulus R,Pass HI,et al. RTOG 0618:stereotactic body radiation therapy (SBRT) to treat operable early-stage lung cancer patients[J]. Proc Am Soc Clin Oncol,2013,31(Supp l):S7523(abstr). [16] Grutters JP,Kessels AG,Pijls-Johannesma M,et al. Comparison of the eff ectiveness of radiotherapy with photons,protons and carbon-ions for non-small cell lung cancer:a meta-analysis[J]. Radiother Oncol,2010,95(1):32-40. DOI:10.1016/j.radonc.2009.08.003. [17] Lou F,Huang J,Sima CS,et al. Patterns of recurrence and second primary lung cancer in early-stage lung cancer survivors followed with routine computed tomography surveillance[J]. J Thorac Cardiovasc Surg,2013,145(1):75-82. DOI:10.1016/j.jtcvs.2012.09.030. [18] Chang JY,Senan S,Paul MA,et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage Ⅰ non-small-cell lung cancer:a pooled analysis of two randomised trials[J]. Lancet Oncol,2015,16(6):630-637. DOI:10.1016/S1470-2045(15)70168-3. [19] Mary KB. Encouraging long-term outcomes reported in patients with stage Ⅰ non-small cell lung cancer treated with stereotactic ablative radiotherapy[J]. CA Cancer J Clin,2017,67(5):349-350. DOI:10.3322/caac.21375. [20] Ginsberg R,Rubinstein L. Randomized trial of lobectomy versus limited resection for T1N0 nonsmall cell lung cancer[J]. Ann Thorac Surg,1995,60:615-622. DOI:10.1016/0003-4975(95)00537-U. [21] Lagerwaard F,Haasbeek C,Smit E,et al. Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage Ⅰ non-small-cell lung cancer[J]. Int J Radiat Oncol Biol Phys,2008,70(3):685-692. DOI:10.1016/j.ijrobp.2007.10.053. [22] Whitson BA,Groth SS,Duval SJ,et al. Surgery for early-stage non-small cell lung cancer:a systematic review of the video-assisted thoracoscopic surgery versus thoracotomy approaches to lobectomy[J]. Ann Thorac Surg,2008,86(6):2008-2016. DOI:10.1016/j.athoracsur.2008.07.009. [23] Paul S,Sedrakyan A,Chiu YL,et al. Outcomes after lobectomy using thoracoscopy vs. thoracotomy:a comparative eff ectiveness analysis utilizing the Nationwide Inpatient Sample database[J]. Eur J Cardiothorac Surg,2013,43(4):813-817. DOI:10.1093/ejcts/ezs428. [24] Boffa DJ,Allen MS,Grab JD,et al. Data from the society of thoracic surgeons general thoracic surgery database:the surgical management of primary lung tumors[J]. J Thorac Cardiovasc Surg,2008,135(2):247-254. DOI:10.1016/j.jtcvs.2007.07.060. [25] Palma D,Lagerwaard F,Rodrigues G,et al. Curative treatment of stage Ⅰ non-small-cell lung cancer in patients with severe COPD:stereotactic radiotherapy outcomes and systematic review[J]. Int J Radiat Oncol Biol Phys,2012,82(3):1149-1156. DOI:10.1016/j.ijrobp.2011.03.005.
2019, Vol. 28 
